98%
921
2 minutes
20
Objectives: The aim of this study was to assess the level and correlates of biomarker-confirmed adherence to isoniazid (INH) preventive therapy (IPT) among children with HIV (CLHIV).
Design: This prospective cohort study assessed adherence among CLHIV on IPT in public sector HIV clinics from 2019 through 2020.
Methods: Adherence was assessed by pill counts or caregiver or self-reports, and urine biomarkers (in-house dipstick and Isoscreen). Both urine biomarker tests detect INH metabolites within 48 h of ingestion. Consistent adherence was defined as having positive results on either biomarker at all visits. Correlates of biomarker-confirmed nonadherence at each visit were evaluated using generalized estimating equations. The in-house dipstick was validated using Isoscreen as the reference.
Results: Among 97 CLHIV on IPT with adherence assessments, median age was 10 years (IQR 7-13). All were on ART at IPT initiation (median duration 46 months [IQR 4-89]); 81% were virally suppressed (<1000 copies/ml). At all visits, 59% ( n = 57) of CLHIV reported taking at least 80% of their doses, while 39% ( n = 38) had biomarker-confirmed adherence. Viral nonsuppression (adjusted risk ratio [aRR] = 1.65; 95% confidence interval [95% CI] 1.09-2.49) and the sixth month of IPT use (aRR = 2.49; 95% CI 1.34-4.65) were independent correlates of biomarker-confirmed nonadherence at each visit. Sensitivity and specificity of the in-house dipstick were 98.1% ( 94.7 - 99.6%) and 94.7% ( 88.1 - 98.3%) , respectively, versus Isoscreen.
Conclusion: Biomarker-confirmed adherence to IPT was sub-optimal and was associated with viral nonsuppression and duration of IPT. Urine dipstick testing may be useful in assessing adherence to IPT in clinical care.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10840836 | PMC |
http://dx.doi.org/10.1097/QAD.0000000000003719 | DOI Listing |
ACS Appl Mater Interfaces
September 2025
School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, U.K.
Tuberculosis (TB), caused by , remains a global health emergency, particularly in low- and middle-income countries. Despite effective pharmacotherapy, prolonged treatment, poor adherence, and drug resistance continue to hinder eradication. Isoniazid (ISZ), a first-line antitubercular drug, is effective but limited by high aqueous solubility and short half-life, necessitating daily administration and causing plasma fluctuations.
View Article and Find Full Text PDFAfr Health Sci
June 2025
Department of Pharmacology and Therapeutics, Makerere University College of Health Sciences.
Background: Tuberculosis(TB) is still among the leading causes of death from a single infectious pathogen worldwide. TB treatment is long, requires multiple drug combinations, and therefore adherence monitoring. TB hair drug levels have been suggested as a technique of treatment adherence monitoring; however, the drug levels might be affected by physiological factors, alcohol use, and cigarette smoking.
View Article and Find Full Text PDFInt Health
August 2025
Department of Psychiatry, College of medicine and Health science, Jigjiga University, P.O. Box 1020, Jigjiga, Ethiopia.
This systematic review and meta-analysis aimed to identify risk factors and mortality rates in HIV and TB co-infected children in Ethiopia. An electronic literature search was conducted using multiple databases, including PubMed, Medline, Web of Science, African Journal Online, Google Scholar and university research repositories for gray literature. Weighted inverse variance random-effects meta-regression was employed to calculate pooled mortality rates, utilizing Stata/SE-17 for analysis.
View Article and Find Full Text PDFTrials
August 2025
UCSF Center for Tuberculosis, University of California, San Francisco, San Francisco, CA, USA.
Background: The standard of care (SOC) treatment for drug-susceptible pulmonary tuberculosis (DS-TB) consists of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE). New treatment regimen options for DS-TB are needed as HRZE is long in duration (6 months), associated with frequent adverse events, unforgiving of adherence lapses, and complicated by rifamycin-based drug-drug interactions. The recent resurgence of TB drug development, particularly in the context of drug-resistant TB, offers promise for additional regimens for persons with DS-TB, provided they are sufficiently effective and well-tolerated.
View Article and Find Full Text PDFBMJ Open
August 2025
Department of Global Health, University of Washington, Seattle, Washington, USA
Introduction: Tuberculosis (TB) remains the leading cause of infectious disease deaths, particularly among people living with HIV (PWH). Despite being preventable, TB preventive therapy (TPT) uptake is low in high-burden regions like South Africa, where new guidelines have expanded TPT eligibility and introduced shorter, more effective regimens like 3 months of weekly rifapentine and isoniazid (3HP). As differentiated service delivery models for HIV care have proven effective, there is increasing recognition that decentralising TPT delivery may improve coverage and completion.
View Article and Find Full Text PDF